The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models

Naratuximab emtansine (IMGN529) is an investigational antibody-drug conjugate consisting of a CD37-targeting antibody conjugated to the maytansine-derived microtuble disruptor, DM1. IMGN529 has shown promising preclinical and clinical activity in non-Hodgkin lymphoma, including diffuse large B-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Hicks, Stuart W., Lai, Katharine C., Gavrilescu, L. Cristina, Yi, Yong, Sikka, Surina, Shah, Prerak, Kelly, Meghan E., Lee, Jenny, Lanieri, Leanne, Ponte, Jose F., Sloss, Callum M., Romanelli, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540712/
https://www.ncbi.nlm.nih.gov/pubmed/28753442
http://dx.doi.org/10.1016/j.neo.2017.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540712/
https://www.ncbi.nlm.nih.gov/pubmed/28753442
http://dx.doi.org/10.1016/j.neo.2017.06.001

Ejemplares similares